263 related articles for article (PubMed ID: 21219545)
1. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.
Bohn AB; Nederby L; Harbo T; Skovbo A; Vorup-Jensen T; Krog J; Jakobsen J; Hokland ME
Eur J Neurol; 2011 Jun; 18(6):919-24. PubMed ID: 21219545
[TBL] [Abstract][Full Text] [Related]
2. Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP.
Klehmet J; Staudt M; Ulm L; Unterwalder N; Meisel A; Meisel C
J Neuroimmunol; 2015 Jun; 283():17-22. PubMed ID: 26004151
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
4. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
5. NK cell markers predict the efficacy of IV immunoglobulins in CIDP.
Mausberg AK; Heininger MK; Meyer Zu Horste G; Cordes S; Fleischer M; Szepanowski F; Kleinschnitz C; Hartung HP; Kieseier BC; Stettner M
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33008921
[TBL] [Abstract][Full Text] [Related]
6. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
van Doorn PA; Kuitwaard K; Jacobs BC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
[TBL] [Abstract][Full Text] [Related]
7. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
Wong AH; Fukami Y; Sudo M; Kokubun N; Hamada S; Yuki N
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):275-9. PubMed ID: 25814494
[TBL] [Abstract][Full Text] [Related]
8. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
10. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
12. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
13. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
[TBL] [Abstract][Full Text] [Related]
14. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
15. CD16+CD57- natural killer cells in multifocal motor neuropathy.
Mizutani K; Oka N; Kaji R; Matsui M; Asanuma K; Kubori T; Kojima Y; Kanda M; Kawanishi T; Tomimoto H; Akiguchi I; Shibasaki H
Eur Neurol; 2005; 53(2):64-7. PubMed ID: 15753615
[TBL] [Abstract][Full Text] [Related]
16. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity.
Jacobi C; Claus M; Wildemann B; Wingert S; Korporal M; Römisch J; Meuer S; Watzl C; Giese T
Clin Immunol; 2009 Dec; 133(3):393-401. PubMed ID: 19828380
[TBL] [Abstract][Full Text] [Related]
17. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
[TBL] [Abstract][Full Text] [Related]
18. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.
Sanvito L; Makowska A; Gregson N; Nemni R; Hughes RA
Autoimmunity; 2009; 42(8):667-77. PubMed ID: 19886739
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
